secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2026-07-15T20:58:01+00:00
Accession:  0001628280-26-048347
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crescent Biopharma prices $125M public offering of shares and pre-funded warrants
--------------------------------------------------------------------------------

- Priced 8,094,793 ordinary shares at $14.50/share and 525,897 pre-funded warrants at $14.499 each.
- Gross proceeds ~$125M; net proceeds ~$115.9M (~$133.5M if underwriters' option exercised in full).
- Underwriters granted 30-day option to purchase up to 1,293,103 additional ordinary shares.
- Net proceeds expected to fund operations into second half of 2028; closing expected July 16, 2026.
- Jefferies, TD Cowen, Guggenheim Securities, Cantor act as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026048347/0001628280-26-048347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026048347/cbio-20260714.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-048347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer